canakinumab
novartis
['nsclc', 'canakinumab', 'lung', 'sclc', 'lcsm,(-blcsm)', 'canopy-a']
canopy-a: adjuvant canakinumab in patients with completely resected nsclc by dr. edward garon. another negative result in the canopy series. the original cantos population that did not have "clinical" lung cancer might actually be the best indication!? #lcsm #esmo22 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC